title: Colchicine in addition to conventional therapy for pericarditis recurrence : An update meta-analysis.
abstract: BACKGROUND
  Randomized controlled trials (RCTs) have investigated the use of colchicine and conventional therapy for reducing the recurrence of pericarditis in patients with acute pericarditis or post-pericardiotomy syndrome. However, the benefits of these treatments are variable.
  
  
  METHODS
  Studies were retrieved from PubMed, the Cochrane Library, and the EMBASE database.
  
  
  RESULTS
  We identified nine RCTs with 1832 patients and a mean follow-up of 13.1 months. Overall, colchicine therapy significantly decreased the risk of pericarditis recurrence (odds ratio, OR 0.42; 95 % confidence interval, CI 0.33-0.52; P < 0.001; I2= 17.0 %). Colchicine therapy was associated with significantly lower rates of pericarditis-associated rehospitalization (OR 0.29; 95 % CI 0.16-0.53; P < 0.0001; I2= 0.0 %) and persistence of symptoms (OR 0.29; 95 % CI, 0.21-0.41; P = 0.000; I2= 0.0 %) at 72 h. Adverse events were higher in the colchicine group (relative risk, RR 1.48; 95 % CI, 1.06-2.07; P = 0.02; I2= 0.0 %). Subgroup analysis showed that recurrence of pericarditis was significantly lower in the colchicine therapy group, irrespective of prednisone use and the cause of pericarditis.
  
  
  CONCLUSIONS
  Colchicine significantly decreases the rate of pericarditis recurrence, regardless of prednisone use and the cause of pericarditis. Larger studies are needed to confirm this effect.
authors.affiliation: Health Division of Guard Bureau, General staff Department of Chinese PLA, Beijing, China.
authors.forename: Y-L
authors.initials: YL
authors.lastname: Li
authors.affiliation: Department of Cardiology, The People's Hospital of Rizhao, Rizhao, Shandong, China.
authors.forename: S-B
authors.initials: SB
authors.lastname: Qiao
authors.affiliation: Department of Cardiovascular Surgery, The Second People's Hospital of Yunnan Province, Kunming, Yunnan, China.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Wang
authors.affiliation: Department of Pediatrics, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
authors.forename: Y-M
authors.initials: YM
authors.lastname: Chen
authors.affiliation: Health Division of Guard Bureau, General staff Department of Chinese PLA, Beijing, China.
authors.forename: J
authors.initials: J
authors.lastname: Luo
authors.affiliation: Health Division of Guard Bureau, General staff Department of Chinese PLA, Beijing, China. zhanghaifeng201406@126.com.
authors.forename: H-F
authors.initials: HF
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D003078:Colchicine / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010493:Pericarditis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control*; D011241:Prednisone / Q000008:administration & dosage*; D015995:Prevalence; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D003078:Colchicine; D011241:Prednisone
keywords: Adverse event; Post-pericardiotomy syndrome; Prednisone; Randomized controlled trials; Recurrence